Business
CalciMedica Announces Proposed Public Offering of Common Stock
LA JOLLA, Calif., Oct. 30, 2024 /PRNewswire/ -- CalciMedica, Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company
About this update from Calcimedica, Inc.
[{"type":"text","content":"LA JOLLA, Calif., Oct. 30, 2024 /PRNewswire/ -- CalciMedica, Inc. (\"CalciMedica\" or the \"Company\") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (\"CRAC\") channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that it has commenced an underwritten public offering of its shares of common stock.\n\n \n \n \n \n \n \n\n \nAll of the shares to be sold in the underwritten public offering are to be sold by the Company. In connection with the proposed offering, the Company expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.\nJones is acting as the sole book-running manager for the offering.\nThe underwritten public offering is being made pursuant to a shelf registration statement on Form S-3 (File No. 333-273949) (including a base prospectus) previously filed with the Securities and Exchange Commission (the \"SEC\") on August 11, 2023 and declared effective by the SEC on August 18, 2023. A preliminary prospectus supplement and the accompanying prospectus relating to and describing the terms of the underwritten public offering will be filed with the SEC and will be available on the SEC's website at www.sec.gov. When available, electronic copies of the preliminary prospectus supplement and the accompanying prospectus relating to the underwritten public offering may also be obtained by contacting: JonesTrading Institutional Services LLC, Attention: Equity Capital Markets, 325 Hudson Street, 6th Floor New York, New York 10013; email: [email protected].\nThis press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.\nAbout CalciMedicaCalciMedica is a clinical-stage biopharmaceutical company focused on developing novel CRAC channel inhibition therapies for inflammat...